Project Details
Description
A Phase 2, Pilot, Multicenter, Randomized, Placebo-Controlled, Sequential, Ascending Dose Study to Characterize the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Activity of CC-930 in Subjects with Recalcitrant Discoid Lupus Erythematosus (DL
| Status | Finished |
|---|---|
| Effective start/end date | 3/1/12 → 2/28/14 |
Funding
- CELGENE CORPORATION
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.